About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive ...
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...
Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell ...
1monon MSN
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of multiple joints, with regulatory T (Treg) ...
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...
Quell has developed considerable expertise in process development and manufacture of CAR-Treg product candidates, which is being used to deliver scaled and consistently high-quality product for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback